Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Total Non-current Assets
All assets not expected to be converted to cash within one year.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 102.8% from a year ago
Total non-current assets stood at $5.01M at the end of Q1 FY2026, up 102.8% from a year earlier and down 5.4% from the prior quarter. Over 3 fiscal years it compounded at +171.0% a year.
Context
- Total non-current assets amounted to 5.1% of total assets at the end of Q1 FY2026, up 3.5 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +102.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 5.3M USD
- Year-over-year change
- +57.1%
- 3-year CAGR
- +171.0%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.3M | +57.1% |
| FY2024 | 2024-12-31 | 3.37M | +1906.0% |
| FY2023 | 2023-12-31 | 168K | -36.8% |
| FY2022 | 2022-12-31 | 266K | — |
Total Non-current Assets vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 total non-current assets of $5.01M is the 8th highest of the 11 companies compared; the peer median is $22.67M.
- Its year-over-year change of +102.8% is the 3rd highest of 11, against a peer median of -6.4%.
- Total non-current assets amounts to 5.1% of total assets for AARD, versus a peer median of 16.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $136.29M | +70.1% | +3.5% | 43.3% | |
| Mar 2026 | $78.95M | -8.3% | -19.4% | 44.4% | |
| Mar 2026 | $38.51M | -22.2% | -21.4% | 28.5% | |
| Mar 2026 | $34.1M | +2.5% | -13.3% | 15.4% | |
| Mar 2026 | $26.62M | -52.8% | -35.7% | 17.9% | |
| Mar 2026 | $18.73M | -22.0% | -7.8% | 29.1% | |
| Mar 2026 | $11.06M | -4.5% | -13.0% | 11.1% | |
| Mar 2026 | $5.01M | +102.8% | +171.0% | 5.1% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $3.24M | +416.8% | +13.4% | 2.2% |
| Mar 2026 | $2.9M | -17.0% | -14.3% | 1.2% | |
ZURAZura Bio Limited | Mar 2026 | $1.64M | +103.6% | -22.3% | 0.7% |
| Peer median (excluding AARD) | $22.67M | -6.4% | -13.8% | 16.6% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.